UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 878

Sortiert nach

Cancer Turns 75

Cancer, 2023-07, Vol.129 (13), p.1959-1961

Ramalingam, Suresh S.

2023

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions

PloS one, 2013-11, Vol.8 (11), p.e81162

2013

Link zum Volltext

Verfügbarkeit prüfen

Lung cancer: New biological insights and recent therapeutic advances

CA: a cancer journal for clinicians, 2011-03, Vol.61 (2), p.91-112

2011

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Link zum Volltext

Verfügbarkeit prüfen

Personalized therapy for lung cancer: striking a moving target

JCI insight, 2018-08, Vol.3 (15)

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Cancer, 2018-01, Vol.124 (2), p.271-277

2018

Link zum Volltext

Verfügbarkeit prüfen

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors in advanced non–small cell lung cancer

Cancer, 2018-01, Vol.124 (2), p.248-261

2018

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4106-4111

2015

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Japanese journal of clinical oncology, 2019-01, Vol.49 (1), p.29-36

2019

Link zum Volltext

Verfügbarkeit prüfen

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Cancer, 2017-11, Vol.123 (21), p.4099-4105

2017

Link zum Volltext

Verfügbarkeit prüfen

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Cancer letters, 2016-10, Vol.380 (2), p.494-504

2016

Link zum Volltext

Verfügbarkeit prüfen

ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

Cancer, 2014-08, Vol.120 (16), p.2392-2402

2014

Link zum Volltext

Verfügbarkeit prüfen

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

Cancer, 2015-04, Vol.121 (8), p.E1-E6

2015

Link zum Volltext

Verfügbarkeit prüfen

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Clinical cancer research, 2017-11, Vol.23 (21), p.6567-6579

2017

Link zum Volltext

Verfügbarkeit prüfen

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature communications, 2023-02, Vol.14 (1), p.1070-1070, Article 1070

2023

Link zum Volltext

Verfügbarkeit prüfen

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

Journal of thoracic oncology, 2020-09, Vol.15 (9), p.1434-1448

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.60-67

2020

Link zum Volltext

Verfügbarkeit prüfen

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers

Cancer, 2020-08, Vol.126 (16), p.3788-3799

2020

Link zum Volltext

Verfügbarkeit prüfen

mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection

The Journal of clinical investigation, 2023-01, Vol.133 (2)

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Cancer research (Chicago, Ill.), 2021-09, Vol.81 (18), p.4822-4834

2021

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3337-3344

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 878

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(782)
Mit Volltextzugriff
(838)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(483)
Life Sciences & Biomedicine
(406)
Humans
(359)
Oncology
(328)
Lung Neoplasms - Drug Therapy
(182)
Female
(174)
Male
(174)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(160)
Aged
(141)
Middle Aged
(140)
Lung Neoplasms - Pathology
(124)
Lung Cancer
(118)
Carcinoma, Non-Small-Cell Lung - Pathology
(97)
Adult
(94)
Mutation
(93)
Lung Neoplasms - Genetics
(85)
Tumors
(78)
Aged, 80 And Over
(74)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(73)
Carcinoma, Non-Small-Cell Lung - Genetics
(70)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(198)
Journal Of Thoracic Oncology
(81)
Cancer
(64)
Cancer Research
(49)
Clinical Lung Cancer
(30)
Clinical Cancer Research
(21)
The New England Journal Of Medicine
(17)
Lung Cancer
(15)
The Oncologist
(11)
The Lancet Oncology
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Cancer Turns 75

Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions

Lung cancer: New biological insights and recent therapeutic advances

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Personalized therapy for lung cancer: striking a moving target

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Immune checkpoint inhibitors in advanced non–small cell lung cancer

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers

mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suchergebnisse filtern